- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: chiauranib (pseudo INN) | CS-2164 | example 32 [US20100298358A1]
Compound class: Synthetic organic
Comment: CS2164 is a multi-target kinase inhibitor that exerts anti-angiogenic, anti-mitotic and anti-inflammatory effects that mediate anti-tumour activity . Via inhibition of Aurora B CS2164 mediates inhibition of histone 3 (H3) phosphorylation which is associated with cell cycle arrest. CS2164 was developed by Chipscreen Biosciences and is claimed in their patent US20100298358A1 .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Deng M, Shi Y, Chen K, Zhao H, Wang Y, Xie S, Zhao J, Luo Y, Fang Z, Fan Y et al.. (2018)
CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo.
Exp Cell Res, 369 (2): 356-362. [PMID:29864401]
2. Lu X-P, Li Z, Yu J, Ning Z. (2010)
Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors.
Patent number: US20100298358A1. Assignee: SHENZHEN CHIPSCREEN BIOSCIENCES, LTD.. Priority date: 22/05/2009. Publication date: 25/11/2010.
3. Zhou Y, Shan S, Li ZB, Xin LJ, Pan DS, Yang QJ, Liu YP, Yue XP, Liu XR, Gao JZ et al.. (2017)
CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.
Cancer Sci, 108 (3): 469-477. [PMID:28004478]